Rgenta Therapeutics

formerly Rgenta

Oral small-molecule RNA-targeting medicines for oncology and neurological disorders

Cambridge, United States · Founded 2018 · $52.0M raised

Employees
11–50
Founded
2018
Business Model
B2B
Total Funding
$52.0M
Last Round
$52.0M Series ANov 2022
Rounds
1

About

Rgenta Therapeutics is a clinical-stage biopharmaceutical company developing oral, small-molecule RNA-targeting medicines focused on oncology and neurological disorders. The company applies a proprietary platform that uses genomic data to identify high-impact RNA target sites, then selects molecules from specialized compound libraries designed to engage those sites and RNA-binding regulatory proteins. By modulating RNA function with high specificity, Rgenta aims to prevent the production of disease-associated proteins and unlock therapies for previously 'undruggable' targets. Its lead program, RGT-61159, is advancing through clinical trials.

Summary

Rgenta Therapeutics is a Biotech company based in Cambridge, United States, founded in 2018. It has raised $52.0M in total across 1 round, most recently a $52.0M Series A round in Nov 2022.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries ANov 2022
$52.0M

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Rgenta Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/rgenta-therapeutics"><img src="https://indexed.vc/api/badge/company/rgenta-therapeutics" alt="Rgenta Therapeutics on Indexed.vc" width="260" height="76" /></a>